Sign in or create an account to add this stock to your watchlist.
About Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LXRX
CUSIP52887210
Phone281-863-3000
Debt
Debt-to-Equity Ratio8.85
Current Ratio2.72
Quick Ratio2.70
Price-To-Earnings
Trailing P/E Ratio-7.76
Forward P/E Ratio-7.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$90.33 million
Price / Sales11.54
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book20.10
Profitability
EPS (Most Recent Fiscal Year)($1.27)
Net Income$-129,050,000.00
Net Margins-140.09%
Return on Equity-213.32%
Return on Assets-36.99%
Miscellaneous
Employees174
Outstanding Shares105,830,000
Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
How were Lexicon Pharmaceuticals' earnings last quarter?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.03. The biopharmaceutical company had revenue of $25.21 million for the quarter, compared to analyst estimates of $25.30 million. Lexicon Pharmaceuticals had a negative net margin of 140.09% and a negative return on equity of 213.32%. The company's quarterly revenue was up 37.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.33) earnings per share. View Lexicon Pharmaceuticals' Earnings History.
What price target have analysts set for LXRX?
6 Wall Street analysts have issued twelve-month price objectives for Lexicon Pharmaceuticals' shares. Their predictions range from $10.00 to $40.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $24.40 in the next year. View Analyst Ratings for Lexicon Pharmaceuticals.
What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (5/8/2018)
- 2. Wedbush analysts commented, "Management announced the initiation of its second global Phase 2/3 clinical trial for Plinabulin (for the prevention of chemotherapy-induced neutropenia CIN). Study 106, initiated in China, is enrolling patients who receive TAC (taxotere, doxorubicin and cyclophosphamide) chemotherapy, which often results in severe neutropenia, to demonstrate Plinabulin’s superiority compared with Neulasta, a G-CSF." (11/30/2017)
- 3. Cowen Inc analysts commented, "Xermelo’s US launch is off to a solid start with 2Q sales of $3.6MM just ahead of." (8/1/2017)
Who are some of Lexicon Pharmaceuticals' key competitors?
Some companies that are related to Lexicon Pharmaceuticals include Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT) and The Medicines (MDCO).
Who are Lexicon Pharmaceuticals' key executives?
Lexicon Pharmaceuticals' management team includes the folowing people:
- Mr. Lonnel Coats, Pres, CEO & Director (Age 53)
- Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 53)
- Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 55)
- Dr. Praveen Tyle, Exec. VP of R&D (Age 58)
- Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 59)
Has Lexicon Pharmaceuticals been receiving favorable news coverage?
Media headlines about LXRX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a news impact score of 0.11 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Lexicon Pharmaceuticals' major shareholders?
Lexicon Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.99%), USS Investment Management Ltd (2.59%), Sector Gamma AS (0.81%), Pinnacle Associates Ltd. (0.75%), Northern Trust Corp (0.54%) and Schwab Charles Investment Management Inc. (0.21%). Company insiders that own Lexicon Pharmaceuticals stock include James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.
Which major investors are selling Lexicon Pharmaceuticals stock?
LXRX stock was sold by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, BlackRock Inc., Pinnacle Associates Ltd., DekaBank Deutsche Girozentrale, New York State Common Retirement Fund, GSA Capital Partners LLP, Northern Trust Corp and Wells Fargo & Company MN. View Insider Buying and Selling for Lexicon Pharmaceuticals.
Which major investors are buying Lexicon Pharmaceuticals stock?
LXRX stock was acquired by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, UBS Group AG, Victory Capital Management Inc., Cim Investment Mangement Inc., A.R.T. Advisors LLC, Virginia Retirement Systems ET AL, Trexquant Investment LP and Sector Gamma AS. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.
How do I buy shares of Lexicon Pharmaceuticals?
Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lexicon Pharmaceuticals' stock price today?
One share of LXRX stock can currently be purchased for approximately $9.85.
How big of a company is Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals has a market capitalization of $1.06 billion and generates $90.33 million in revenue each year. The biopharmaceutical company earns $-129,050,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Lexicon Pharmaceuticals employs 174 workers across the globe.
How can I contact Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.
MarketBeat Community Rating for Lexicon Pharmaceuticals (LXRX)
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Lexicon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $24.40, suggesting that the stock has a possible upside of 147.72%. The high price target for LXRX is $40.00 and the low price target for LXRX is $10.00. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.33 | 2.20 | 2.50 | 2.80 |
| Ratings Breakdown: | 1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $24.40 | $24.50 | $24.80 | $28.75 |
| Price Target Upside: | 147.72% upside | 202.84% upside | 166.95% upside | 138.99% upside |
Lexicon Pharmaceuticals (NASDAQ:LXRX) Consensus Price Target History
Lexicon Pharmaceuticals (NASDAQ:LXRX) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Lexicon Pharmaceuticals (NASDAQ:LXRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Lexicon Pharmaceuticals (NASDAQ LXRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.10%
Lexicon Pharmaceuticals (NASDAQ LXRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/17/2017 | Public Equities L.P. Invus | Director | Buy | 180,727 | $10.11 | $1,827,149.97 | |  |
| 11/15/2017 | Lonnel Coats | CEO | Buy | 10,000 | $9.91 | $99,100.00 | 42,985 | |
| 11/14/2017 | Jeffrey L Wade | EVP | Buy | 2,000 | $9.48 | $18,960.00 | 50,597 | |
| 11/14/2017 | Public Equities L.P. Invus | Director | Buy | 575,946 | $9.64 | $5,552,119.44 | | |
| 11/10/2017 | Public Equities L.P. Invus | Director | Buy | 145,680 | $9.74 | $1,418,923.20 | | |
| 9/15/2017 | Lonnel Coats | Insider | Buy | 30,000 | $12.54 | $376,200.00 | | |
| 9/15/2017 | Sam L Barker | Director | Buy | 1,000 | $12.50 | $12,500.00 | 25,623 | |
| 6/6/2016 | James F Tessmer | VP | Sell | 1,500 | $15.00 | $22,500.00 | 17,446 | |
| 5/23/2016 | James F Tessmer | VP | Sell | 6,000 | $13.00 | $78,000.00 | 21,946 | |
| 12/12/2014 | C.V. Invus | Director | Buy | 150,000 | $0.88 | $132,000.00 | | |
| 12/10/2014 | C.V. Invus | Director | Buy | 315,896 | $0.90 | $284,306.40 | | |
| 11/26/2014 | International S.C.A. Artal | Director | Buy | 149,253,731 | $1.01 | $150,746,268.31 | | |
| 10/25/2013 | Bryan A Kleinlein | CFO | Sell | 227,626 | $0.13 | $29,591.38 | | |
| 10/9/2013 | Bryan A Kleinlein | CFO | Sell | 83,281 | $0.19 | $15,823.39 | | |
| 7/9/2013 | Bryan A Kleinlein | CFO | Sell | 88,235 | $0.11 | $9,705.85 | | |
| 6/27/2013 | Alexander Richard Walsh | CEO | Sell | 160,000 | $0.13 | $20,800.00 | | |
| 6/18/2013 | Alexander Richard Walsh | CEO | Sell | 220,000 | $0.18 | $39,600.00 | | |
| 6/7/2013 | Alexander Richard Walsh | CEO | Sell | 170,000 | $0.19 | $32,300.00 | | |
| 11/21/2012 | Alexander Richard Walsh | CEO | Sell | 23,700 | $0.34 | $8,058.00 | | |
| 10/23/2012 | International S.C.A. Artal | Director | Buy | 3,000,000 | $2.25 | $6,750,000.00 | | |
| 10/3/2012 | Alexander Richard Walsh | CEO | Sell | 25,000 | $0.30 | $7,500.00 | | |
(Data available from 1/1/2013 forward)
Lexicon Pharmaceuticals (NASDAQ LXRX) News Headlines
| Source: |
|
Lexicon Pharmaceuticals (NASDAQ:LXRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Lexicon Pharmaceuticals (NASDAQ:LXRX) Income Statement, Balance Sheet and Cash Flow Statement
Lexicon Pharmaceuticals (NASDAQ LXRX) Stock Chart for Monday, May, 21, 2018
Loading chart…
